title: Canakinumab for gout attacks. Too risky.
abstract: There are no clinical trials of canakinumab in patients with gout attacks refractory to several prior treatments. Adverse effects mainly include infections, hypersensitivity reactions and dizziness.
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D004342:Drug Hypersensitivity / Q000209:etiology; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C541220:canakinumab